COGNITION THERAPEUTICS INC Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from Q1 2021 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Summary
Cognition Therapeutics Inc quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from Q1 2021 to Q2 2023.
  • Cognition Therapeutics Inc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending June 30, 2023 was -$4.73M, a 19.6% increase year-over-year.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 -$4.73M +$1.15M +19.6% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-08
Q1 2023 -$6.17M -$2.46M -66.2% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-04
Q2 2022 -$5.88M -$4.39M -294% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$3.71M -$3.94M -1765% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q2 2021 -$1.49M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $223K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.